Related Experiment Video
Updated: Jan 14, 2026
Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims
Yoshihiro Noguchi1, Ai Oonishi2, Rikuto Masuda2
1Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigakunishi, Gifu-shi, 501-1196, Gifu, Japan; Laboratory of Medical Collaborative Pharmacy, Gifu Pharmaceutical University, 1-25-4, Daigakunishi, Gifu-shi, 501-1196, Gifu, Japan.
Introduction:
Multi-acting receptor-targeted antipsychotics (MARTA) like asenapine, olanzapine, quetiapine, and clozapine are second-generation antipsychotics linked to adverse metabolic effects, including weight gain and elevated blood glucose, which may raise the risk of pancreatitis. This study investigates the relationship between MARTA use and pancreatitis using the DeSC claims database in Japan.
Methods:
A sequence symmetry analysis (SSA) was conducted on data from 2014 to 2023, focusing on patients prescribed MARTA agents and diagnosed with pancreatitis. Adjusted Sequence Ratios (ASRs) were used to assess the risk, and the time from MARTA initiation to pancreatitis onset was analyzed.
Results:
The use of all MARTA agents was significantly associated with an increased risk of pancreatitis. The ASR was 1.84 (95 % CI: 1.74-1.94) for asenapine, 6.04 (95 % CI: 4.63-7.89) for clozapine, 3.08 (95 % CI: 3.01-3.15) for olanzapine, and 2.31 (95 % CI: 2.27-2.34) for quetiapine. These findings indicate a statistically significant increase in pancreatitis risk following the initiation of MARTA. Additionally, the median time from the start of MARTA therapy to the onset of pancreatitis was 650 days for asenapine, 864.5 days for clozapine, 612 days for olanzapine, and 613 days for quetiapine, suggesting that pancreatitis tends to develop after prolonged use, especially with clozapine.
Discussion:
These results highlight the need for careful monitoring of pancreatitis in patients receiving long-term MARTA therapy. In individuals with risk factors such as obesity, diabetes, or dyslipidemia, the use of MARTA should be considered cautiously. Early detection and appropriate management are essential to reduce the risk of serious outcomes.
More Related Videos
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
07:10Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
Related Concept Videos
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:26Psychosis: Goals of Pharmacotherapy
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:28Psychosis and Antipsychotic Drugs: Overview
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists